Today & Thurs., our CMO, Paul Woodard will attend the Annual #Cholangiocarcinoma Foundation Conference in Salt Lake City, UT. We’re looking forward to uniting with other passionate experts who are fearlessly working to find a cure. Be sure to say "Hi!" Cholangiocarcinoma Foundation

We have great news to share at #AACR23! Data from our Ph 1 study show encouraging clinical benefit for IO-108 as a monotherapy & when combined with pembrolizumab. Don't miss the oral presentation on Tue., Apr. 18 at 4:05-4:15 PM (CT040). Read more at: bit.ly/3KDIlKY

At #AACR23 tomorrow, our team will present late-breaking #preclinical data for IO-312. The data will show that our first-in-class LILRB4 x CD3 #bispecific antibody led to potent & specific killing of monocytic #AML cells in vitro & in vivo. Stop by! bit.ly/3KDIlKY

Today at #AACR23, don't miss an oral presentation at 4:05pm that will detail encouraging Ph 1 data for our first-in-class #myeloid #checkpointinhibitor, IO-108. Join the session to learn why #LILRB2 is a critically important #immunotherapy target. bit.ly/3KDIlKY

We're thrilled to share that our IO-108 Phase 1 investigator was featured in OncLive.com’s coverage of #AACR23. Thank you OncLive.com for sharing our story! bit.ly/3GZRIUj

Thank you to all who joined us for our oral and late-breaking presentations at #AACR23. If you’re interested in learning more about our pioneering work in #myeloid #checkpointinhibitors, we invite you to explore our science and pipeline: immune-onc.com/pipeline

Thank you MedicalResearch.com for this comprehensive article about the encouraging Phase 1 dose escalation data presented at #AACR23 for our first-in-class #myeloid #checkpointinhibitor, IO-108. Read the full article here: bit.ly/41qqXR2

Today, we will be at the annual Stanford Drug Discovery Symposium. Yesterday, our CEO Charlene Liao had the pleasure of speaking with Dr. Brian Druker, recipient of the 2023 Stanford Drug Discovery Symposium Lifetime Achievement Award. If you're at #SDDS2023, please say Hello!

#DYK that myeloid checkpoints could be game-changing targets for the field of #cancerimmunotherapy? Join our CEO Charlene Liao's presentation at the Cambridge Healthtech Institute's 2nd Annual “Emerging Targets for Oncology and Beyond” conference at #PEGS23 next week. See you there!

We are presenting clinical data for IO-202 for the first time at #EHA2023 next month! IO-202 is our first-in-class #myeloid #checkpointinhibitor targeting LILRB4 (aka ILT3) for the treatment of #AML and #CMML. Read below for info to attend the presentation ⬇️

Why are we so excited about #immunotherapy? Because we’re playing a big role in its evolution. This week at #PEGS23 our CEO, Charlene Liao discussed our scientific approach and robust pipeline targeting myeloid checkpoints. Learn more at Immune-Onc.com

Next Tue., May 23, our CEO Charlene Liao and CFO Chris Whitmore look forward to meeting with investors 1:1 at the 2023 Wells Fargo Virtual Private Biotech Symposium to discuss how our platform of #myeloid #checkpointinhibitors is reigniting the field of #immunotherapy. #biotech

#DYK that our first-in-class humanized IgG1 monoclonal antibody, IO-202, targets the myeloid inhibitory receptor LILRB4 to reverse immune suppression in the tumor microenvironment? Visit our first clinical data presentation showing this in action at #EHA2023.

#Breaking: Our team and investigators will share the first clinical data on IO-202 (anti-LILRB4), our first-in-class #myeloid #checkpointinhibitor for the treatment of #AML and #CMML at the #EHA2023 congress in Frankfurt. Learn more: immune-onc.com/pr-posts/immun…

Next week at the 3rd Tumor Myeloid-Targeted Therapies Summit in Boston, our very own Dr. Luke Chung will present encouraging Ph 1 data for IO-108, our first-in-class antibody targeting LILRB2 (ILT4). We hope to see you there (Wed., 7/19 - 1:30 PM)! bit.ly/3rhgQka

Excited to share a collaboration with Roche evaluating IO-108 in combination with atezolizumab (Tecentriq®) and bevacizumab (Avastin®) for the 1st line treatment of patients with locally advanced or metastatic and/or unresectable hepatocellular carcinoma bit.ly/3I42pFk

Great news! The FDA has granted IO-202 Orphan Drug Designation for the treatment of chronic myelomonocytic leukemia (CMML). Our Ph 1 study of IO-202 in combination with azacitidine is also currently enrolling newly diagnosed CMML patients. Read more here: bit.ly/48pyWQT

Exciting News! The San Francisco Business Times recognized our Orphan Drug Designation for IO-202 for #CMML as a recent breakthrough by women-led life sciences companies in the Bay Area. Read more here: bizjournals.com/sanfrancisco/n…

#News: We look forward to presenting interim clinical data from our Phase 1b trial of IO-202 for the treatment of chronic myelomonocytic leukemia (#CMML) at the upcoming #EHA2024 Congress. View the press release for details: bit.ly/4bjpnoQ

New from Immune-Onc Therapeutics at #EHA2024! Today, we will present additional positive interim Ph 1b expansion data for IO-202 in #CMML patients. The study shows early and sustained complete remissions among patients, regardless of their prognosis or mutation status. bit.ly/3Rs1SC7